Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial (Q28257600)

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Alogliptin for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

A note on the making of culinary tradition--an example of modern Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Efficacy and safety of incretin based therapies: clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-012-9596-0

Alogliptin: a new addition to the class of DPP-4 inhibitors

21 January 2018

1 reference

12 December 2020

[Pharmacological and clinical profile of alogliptin benzoate (NESINA®)]

1 reference

12 December 2020

Traditional Japanese dietary basics: a solution for modern health issues?

1 reference

12 December 2020

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

1 reference

12 December 2020

[Diagnostic criteria for diabetes mellitus].

1 reference

12 December 2020